Celgene to Acquire Receptos, Advancing the Potential of Ozanimod for the Treatment of Ulcerative Colitis

Celgene to Acquire Receptos, Advancing the Potential of Ozanimod for the Treatment of Ulcerative Colitis
This week Celgene Corporation, a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation, announced that it has signed an agreement in which it will acquire Receptos, Inc. (NASDAQ: RCPT) a biopharmaceutical company that specializes in the  development of therapeutic candidates for the treatment of immune and metabolic diseases. According to the companies, the acquisition will: Current clinical trials including the phase III TRUE NORTH trial (data to be released in 2018), and the phase III RADIANCE (data to be released in 2017), have the potential to position Ozanimod as the first drug of its kind to be be approved for IBD. In a company-wide announcement, Faheem Hasnain, President and Chief Executive Officer of Receptos, stated,  “In Celgene, we have found the ideal partner to maximize the potential of Ozanimod and our promising pipeline in order to impro
Subscribe or to access all post and page content.